Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana M Gonzalez-Angulo

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Molecular Cancer Therapeutics|April 15, 2011
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancerAna M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, et al.
Cancer|March 13, 2009
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton, Shannon N Westin, Kaylene Ready, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinaseChandra Bartholomeusz, Ana M Gonzalez-Angulo, Anna Kazansky, et al.
The Oncologist|April 12, 2013
Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancerJennifer K Litton, Carla L Warneke, Karin M Hahn, et al.
American Journal of Clinical Oncology|May 8, 2013
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed TherapyChiaojung Jillian Tsai, Jing Li, Ana M Gonzalez-Angulo, et al.
Breast Cancer Research and Treatment|August 11, 2011
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, et al.
Cancer Research|May 14, 2009
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancerTodd W Miller, Marianela Pérez-Torres, Archana Narasanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2015
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain MetastasesIshwaria M Subbiah, Xiudong Lei, Jeffrey S Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomesElizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2013
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypesMariana Chavez-Macgregor, Shuying Liu, Debora De Melo-Gagliato, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Molecular Cancer Therapeutics|April 15, 2011
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancerAna M Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, et al.
Cancer|March 13, 2009
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton, Shannon N Westin, Kaylene Ready, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinaseChandra Bartholomeusz, Ana M Gonzalez-Angulo, Anna Kazansky, et al.
The Oncologist|April 12, 2013
Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancerJennifer K Litton, Carla L Warneke, Karin M Hahn, et al.
American Journal of Clinical Oncology|May 8, 2013
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed TherapyChiaojung Jillian Tsai, Jing Li, Ana M Gonzalez-Angulo, et al.
Breast Cancer Research and Treatment|August 11, 2011
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, et al.
Cancer Research|May 14, 2009
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancerTodd W Miller, Marianela Pérez-Torres, Archana Narasanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2015
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain MetastasesIshwaria M Subbiah, Xiudong Lei, Jeffrey S Weinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomesElizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 4, 2013
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypesMariana Chavez-Macgregor, Shuying Liu, Debora De Melo-Gagliato, et al.
Pageof 15